Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio s Investigational Compound Being Developed for Patients with AML – Padovanews padovanews.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from padovanews.it Daily Mail and Mail on Sunday newspapers.
Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML Entospletinib is currently being studied in the Phase 3 AGILITY registrational study, with data anticipated in second half of 2023 SAN MATEO, Calif. and SAN DIEGO, Aug. 17, 2022 /PRNewswire/ Kronos Bio, Inc..
Kronos Bio Inc (KRON) and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider.